Research graph
References from Understanding Tryptase Physiology, Clinical Significance, and Diagnostic Applications: Where Do We Stand?. Local targets link to admitted publications; unresolved targets remain external evidence.
Anaphylaxis during anaesthesia: Diagnostic approach
10.1111/j.1398-9995.2007.01347.x · 2007 · External reference
Tryptase in type I hypersensitivity
10.1016/j.anai.2022.08.996 · 2022 · External reference
Tryptase genetics and anaphylaxis
10.1016/j.jaci.2006.02.026 · 2006 · External reference
Mast Cells, Mastocytosis, and Related Disorders
10.1056/nejmra1409760 · 2015 · External reference
10.3390/ijms241512130
10.3390/ijms241512130 · External reference
Mast cell proteases and metastasis
10.1016/j.prp.2024.155801 · 2024 · External reference
Human mast cell tryptase in biology and medicine
10.1016/j.molimm.2014.04.001 · 2015 · External reference
Biology of mast cell tryptase
10.1111/j.1742-4658.2006.05211.x · 2006 · External reference
Human mast cell tryptase isoforms: Separation and examination of substrate-specificity differences
10.1042/bj3070341 · 1995 · External reference
Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number
10.1038/ng.3696 · 2016 · External reference
The Genetic Basis and Clinical Impact of Hereditary Alpha-Tryptasemia
10.1016/j.jaip.2021.03.005 · 2021 · External reference
Hereditary alpha tryptasemia and clinical implications
2025 · External reference
Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions
10.1016/j.jaip.2022.05.003 · 2022 · External reference
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell–Mediated Reactions
10.1007/s11882-024-01136-y · 2024 · External reference
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1
10.1016/j.jaci.2020.06.035 · 2021 · External reference
Severe food allergy reactions are associated with α-tryptase
10.1016/j.jaci.2023.07.014 · 2023 · External reference
The clinical features of hereditary alpha-tryptasemia
2024 · External reference
Expression of α-tryptase and β-tryptase by human basophils
10.1016/j.jaci.2004.02.032 · 2004 · External reference
A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I
10.1172/jci118523 · 1996 · External reference
Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer
10.1016/s0021-9258(17)38401-6 · 1986 · External reference
Regulation of Human Mast Cell β-Tryptase: Conversion of Inactive Monomer to Active Tetramer at Acid pH
10.4049/jimmunol.160.9.4561 · 1998 · External reference
Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions
10.1038/nature14022 · 2015 · External reference
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma
10.1016/j.cell.2019.09.009 · 2019 · External reference
Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System
10.1016/j.jaip.2021.12.031 · 2022 · External reference
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
10.1182/blood.2020006157 · 2021 · External reference
Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis
10.1111/cea.14264 · 2023 · External reference
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes
10.1016/j.jaci.2023.08.015 · 2023 · External reference
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
10.1182/bloodadvances.2022007936 · 2023 · External reference
Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis
10.1056/nejm198706253162603 · 1987 · External reference
The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
10.1172/jci118337 · 1995 · External reference
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
10.1016/j.jaip.2023.08.008 · 2023 · External reference
Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
10.1016/j.jaip.2024.03.010 · 2024 · External reference
Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis
10.1172/jci114051 · 1989 · External reference
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
10.1016/j.jaci.2021.08.007 · 2022 · External reference
Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre
10.1016/j.ejim.2016.01.005 · 2016 · External reference
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
10.1097/hs9.0000000000000646 · 2021 · External reference
Redefining tryptase norms in the pediatric population reveals sex-based differences: Clinical implications
10.1111/all.16365 · 2024 · External reference
Histamine and tryptase levels in patients with acute allergic reactions: An emergency department–based study
10.1067/mai.2000.107600 · 2000 · External reference
Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective
10.1111/all.13226 · 2017 · External reference
Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study
10.1111/all.13752 · 2019 · External reference
Raised tryptase without anaphylaxis or mastocytosis: Heterophilic antibody interference in the serum tryptase assay
10.1111/j.1365-2249.2010.04287.x · 2011 · External reference
False-elevated serum tryptase assay result caused by heterophilic antibodies
10.1016/j.jaci.2005.07.023 · 2005 · External reference
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
10.1016/j.iac.2006.05.010 · 2006 · External reference
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management
10.1016/j.jaci.2019.08.023 · 2019 · External reference
Mast Cell Activation Syndrome: A Review
10.1007/s11882-012-0322-z · 2012 · External reference
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
10.1016/j.jaip.2019.01.006 · 2019 · External reference
Mast Cell Activation Syndrome: Improved Identification by Combined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α
10.1016/j.jaip.2014.06.011 · 2014 · External reference
Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis
10.1056/nejmoa070030 · 2008 · External reference
Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children
10.1111/all.15308 · 2022 · External reference
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome
10.1159/000501079 · 2019 · External reference
EAACI guidelines: Anaphylaxis (2021 update)
10.1111/all.15032 · 2021 · External reference
World Allergy Organization Anaphylaxis Guidance 2020
10.1016/j.waojou.2020.100472 · 2020 · External reference
Identifying patients at risk of anaphylaxis
10.1016/j.waojou.2024.100904 · 2024 · External reference
Anaphylaxis: A 2023 practice parameter update
10.1016/j.anai.2023.09.015 · 2023 · External reference
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
10.1016/j.jaip.2024.08.044 · 2024 · External reference
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal
10.1159/000328760 · 2011 · External reference
Diagnosis and treatment of Hymenoptera venom allergy
10.5414/alx02430e · 2023 · External reference
10.3390/medicina60091380
10.3390/medicina60091380 · External reference
Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management
10.1016/j.jaip.2024.08.034 · 2024 · External reference
Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy
10.1016/j.jaip.2024.08.025 · 2024 · External reference
Reversible Elevation of Tryptase Over the Individual’s Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
10.1007/s11882-024-01124-2 · 2024 · External reference
Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia*
10.1111/j.1399-6576.2007.01313.x · 2007 · External reference
Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease
10.1159/000059404 · 2002 · External reference
The serum tryptase test: An emerging robust biomarker in clinical hematology
10.1586/17474086.2014.955008 · 2014 · External reference
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRα, classification by WHO criteria, and response to therapy with imatinib
10.1016/j.leukres.2005.11.014 · 2006 · External reference
Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease
10.1093/joneph/23.3.282 · 2010 · External reference
Unresolved reference
External reference
Laboratory Investigation of Deaths Due to Anaphylaxis
10.1520/jfs13095j · 1991 · External reference
Mast cell biology in evolution
10.1016/j.jaci.2006.03.031 · 2006 · External reference
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old
10.1159/000510527 · 2020 · External reference
Paediatric perioperative hypersensitivity: The performance of the current consensus formula and the effect of uneventful anaesthesia on serum tryptase
10.1016/j.bjao.2023.100254 · 2024 · External reference
Disease Spectrum of Anaphylaxis Disorders
10.1016/j.jaip.2023.05.012 · 2023 · External reference
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
10.18176/jiaci.0675 · 2021 · External reference
Serum chemistry profiling and prognostication in systemic mastocytosis: A registry-based study of the ECNM and GREM
10.1182/bloodadvances.2024012756 · 2024 · External reference
Diagnostic Evaluation and Classification of Mastocytosis
10.1016/j.iac.2006.05.002 · 2006 · External reference
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria
10.1111/j.1365-2362.2007.01807.x · 2007 · External reference
10.3390/cancers14143474
10.3390/cancers14143474 · External reference
The international consensus classification of mastocytosis and related entities
10.1007/s00428-022-03423-3 · 2022 · External reference
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: A first-in-human clinical trial
10.1093/bjd/ljad191 · 2023 · External reference
Defining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: Are we there yet?
10.23822/eurannaci.1764-1489.288 · 2023 · External reference
Actualización en mastocitosis. Parte 1: Fisiopatología, clínica y diagnóstico
10.1016/j.ad.2015.09.007 · 2016 · External reference
Actualización en mastocitosis. Parte 2: Categorías, pronóstico y tratamiento
10.1016/j.ad.2015.09.009 · 2016 · External reference
Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment
10.1007/s11882-006-0061-0 · 2006 · External reference
Mastocytosis
10.1016/j.iac.2014.01.005 · 2014 · External reference
10.3390/diagnostics13233583
10.3390/diagnostics13233583 · External reference
Pediatric mastocytosis
10.1097/mop.0000000000000922 · 2020 · External reference
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis
10.1111/j.1365-2230.2008.03005.x · 2009 · External reference
Epidemiology of urticaria: A representative cross-sectional population survey
10.1111/j.1365-2230.2010.03840.x · 2010 · External reference
Chronic spontaneous urticaria guidelines: What is new?
10.1016/j.jaci.2022.10.004 · 2022 · External reference
Autoimmune chronic spontaneous urticaria
10.1016/j.jaci.2022.04.010 · 2022 · External reference
The role and relevance of mast cells in urticaria
10.1111/imr.12632 · 2018 · External reference
Serum total tryptase levels are increased in patients with active chronic urticaria
10.1111/j.1365-2222.2010.03582.x · 2010 · External reference
The Utility of Serum Tryptase as a Marker in Chronic Spontaneous Urticaria
10.2340/00015555-1486 · 2013 · External reference
Chronic spontaneous urticaria and chronic inducible urticaria
10.1016/j.jaci.2025.05.019 · 2025 · External reference
Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
2017 · External reference
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
10.1146/annurev-pathmechdis-031521-042618 · 2023 · External reference
Tryptase and histamine may support oral food challenge in the diagnosis of allergy
2015 · External reference
Melanoma-derived extracellular vesicles transfer proangiogenic factors
10.32604/or.2024.055449 · 2025 · External reference
Updates in diagnosis and management of paediatric mastocytosis
10.1097/aci.0000000000000869 · 2022 · External reference
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper
10.1111/all.15889 · 2023 · External reference
The international consensus classification of mastocytosis and related entities
10.1007/s00428-022-03423-3 · ExternalCitation · doi-reference
Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment
10.1007/s11882-006-0061-0 · ExternalCitation · doi-reference
Mast Cell Activation Syndrome: A Review
10.1007/s11882-012-0322-z · ExternalCitation · doi-reference
Reversible Elevation of Tryptase Over the Individual’s Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
10.1007/s11882-024-01124-2 · ExternalCitation · doi-reference
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell–Mediated Reactions
10.1007/s11882-024-01136-y · ExternalCitation · doi-reference
Actualización en mastocitosis. Parte 1: Fisiopatología, clínica y diagnóstico
10.1016/j.ad.2015.09.007 · ExternalCitation · doi-reference
Actualización en mastocitosis. Parte 2: Categorías, pronóstico y tratamiento
10.1016/j.ad.2015.09.009 · ExternalCitation · doi-reference
Tryptase in type I hypersensitivity
10.1016/j.anai.2022.08.996 · ExternalCitation · doi-reference
Anaphylaxis: A 2023 practice parameter update
10.1016/j.anai.2023.09.015 · ExternalCitation · doi-reference
Paediatric perioperative hypersensitivity: The performance of the current consensus formula and the effect of uneventful anaesthesia on serum tryptase
10.1016/j.bjao.2023.100254 · ExternalCitation · doi-reference
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma
10.1016/j.cell.2019.09.009 · ExternalCitation · doi-reference
Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre
10.1016/j.ejim.2016.01.005 · ExternalCitation · doi-reference
Diagnostic Evaluation and Classification of Mastocytosis
10.1016/j.iac.2006.05.002 · ExternalCitation · doi-reference
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
10.1016/j.iac.2006.05.010 · ExternalCitation · doi-reference
Mastocytosis
10.1016/j.iac.2014.01.005 · ExternalCitation · doi-reference
Expression of α-tryptase and β-tryptase by human basophils
10.1016/j.jaci.2004.02.032 · ExternalCitation · doi-reference
False-elevated serum tryptase assay result caused by heterophilic antibodies
10.1016/j.jaci.2005.07.023 · ExternalCitation · doi-reference
Tryptase genetics and anaphylaxis
10.1016/j.jaci.2006.02.026 · ExternalCitation · doi-reference
Mast cell biology in evolution
10.1016/j.jaci.2006.03.031 · ExternalCitation · doi-reference
AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management
10.1016/j.jaci.2019.08.023 · ExternalCitation · doi-reference
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1
10.1016/j.jaci.2020.06.035 · ExternalCitation · doi-reference
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
10.1016/j.jaci.2021.08.007 · ExternalCitation · doi-reference
Autoimmune chronic spontaneous urticaria
10.1016/j.jaci.2022.04.010 · ExternalCitation · doi-reference
Chronic spontaneous urticaria guidelines: What is new?
10.1016/j.jaci.2022.10.004 · ExternalCitation · doi-reference
Severe food allergy reactions are associated with α-tryptase
10.1016/j.jaci.2023.07.014 · ExternalCitation · doi-reference
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes
10.1016/j.jaci.2023.08.015 · ExternalCitation · doi-reference
Chronic spontaneous urticaria and chronic inducible urticaria
10.1016/j.jaci.2025.05.019 · ExternalCitation · doi-reference
Mast Cell Activation Syndrome: Improved Identification by Combined Determinations of Serum Tryptase and 24-Hour Urine 11β-Prostaglandin2α
10.1016/j.jaip.2014.06.011 · ExternalCitation · doi-reference
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
10.1016/j.jaip.2019.01.006 · ExternalCitation · doi-reference
The Genetic Basis and Clinical Impact of Hereditary Alpha-Tryptasemia
10.1016/j.jaip.2021.03.005 · ExternalCitation · doi-reference
Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System
10.1016/j.jaip.2021.12.031 · ExternalCitation · doi-reference
Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions
10.1016/j.jaip.2022.05.003 · ExternalCitation · doi-reference
Disease Spectrum of Anaphylaxis Disorders
10.1016/j.jaip.2023.05.012 · ExternalCitation · doi-reference
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
10.1016/j.jaip.2023.08.008 · ExternalCitation · doi-reference
Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
10.1016/j.jaip.2024.03.010 · ExternalCitation · doi-reference
Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy
10.1016/j.jaip.2024.08.025 · ExternalCitation · doi-reference
Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management
10.1016/j.jaip.2024.08.034 · ExternalCitation · doi-reference
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
10.1016/j.jaip.2024.08.044 · ExternalCitation · doi-reference
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRα, classification by WHO criteria, and response to therapy with imatinib
10.1016/j.leukres.2005.11.014 · ExternalCitation · doi-reference
Human mast cell tryptase in biology and medicine
10.1016/j.molimm.2014.04.001 · ExternalCitation · doi-reference
Mast cell proteases and metastasis
10.1016/j.prp.2024.155801 · ExternalCitation · doi-reference
World Allergy Organization Anaphylaxis Guidance 2020
10.1016/j.waojou.2020.100472 · ExternalCitation · doi-reference
Identifying patients at risk of anaphylaxis
10.1016/j.waojou.2024.100904 · ExternalCitation · doi-reference
Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer
10.1016/s0021-9258(17)38401-6 · ExternalCitation · doi-reference
Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions
10.1038/nature14022 · ExternalCitation · doi-reference
Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number
10.1038/ng.3696 · ExternalCitation · doi-reference
Human mast cell tryptase isoforms: Separation and examination of substrate-specificity differences
10.1042/bj3070341 · ExternalCitation · doi-reference
Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis
10.1056/nejm198706253162603 · ExternalCitation · doi-reference
Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis
10.1056/nejmoa070030 · ExternalCitation · doi-reference
Mast Cells, Mastocytosis, and Related Disorders
10.1056/nejmra1409760 · ExternalCitation · doi-reference
Histamine and tryptase levels in patients with acute allergic reactions: An emergency department–based study
10.1067/mai.2000.107600 · ExternalCitation · doi-reference
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: A first-in-human clinical trial
10.1093/bjd/ljad191 · ExternalCitation · doi-reference
Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease
10.1093/joneph/23.3.282 · ExternalCitation · doi-reference
Updates in diagnosis and management of paediatric mastocytosis
10.1097/aci.0000000000000869 · ExternalCitation · doi-reference
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
10.1097/hs9.0000000000000646 · ExternalCitation · doi-reference
Pediatric mastocytosis
10.1097/mop.0000000000000922 · ExternalCitation · doi-reference
Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective
10.1111/all.13226 · ExternalCitation · doi-reference
Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study
10.1111/all.13752 · ExternalCitation · doi-reference
EAACI guidelines: Anaphylaxis (2021 update)
10.1111/all.15032 · ExternalCitation · doi-reference
Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children
10.1111/all.15308 · ExternalCitation · doi-reference
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper
10.1111/all.15889 · ExternalCitation · doi-reference
Redefining tryptase norms in the pediatric population reveals sex-based differences: Clinical implications
10.1111/all.16365 · ExternalCitation · doi-reference
Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis
10.1111/cea.14264 · ExternalCitation · doi-reference
The role and relevance of mast cells in urticaria
10.1111/imr.12632 · ExternalCitation · doi-reference
Serum total tryptase levels are increased in patients with active chronic urticaria
10.1111/j.1365-2222.2010.03582.x · ExternalCitation · doi-reference
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis
10.1111/j.1365-2230.2008.03005.x · ExternalCitation · doi-reference
Epidemiology of urticaria: A representative cross-sectional population survey
10.1111/j.1365-2230.2010.03840.x · ExternalCitation · doi-reference
Raised tryptase without anaphylaxis or mastocytosis: Heterophilic antibody interference in the serum tryptase assay
10.1111/j.1365-2249.2010.04287.x · ExternalCitation · doi-reference
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria
10.1111/j.1365-2362.2007.01807.x · ExternalCitation · doi-reference
Anaphylaxis during anaesthesia: Diagnostic approach
10.1111/j.1398-9995.2007.01347.x · ExternalCitation · doi-reference
Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia*
10.1111/j.1399-6576.2007.01313.x · ExternalCitation · doi-reference
Biology of mast cell tryptase
10.1111/j.1742-4658.2006.05211.x · ExternalCitation · doi-reference
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
10.1146/annurev-pathmechdis-031521-042618 · ExternalCitation · doi-reference
Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease
10.1159/000059404 · ExternalCitation · doi-reference
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal
10.1159/000328760 · ExternalCitation · doi-reference
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome
10.1159/000501079 · ExternalCitation · doi-reference
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old
10.1159/000510527 · ExternalCitation · doi-reference
Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis
10.1172/jci114051 · ExternalCitation · doi-reference
The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
10.1172/jci118337 · ExternalCitation · doi-reference
A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I
10.1172/jci118523 · ExternalCitation · doi-reference
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
10.1182/blood.2020006157 · ExternalCitation · doi-reference
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
10.1182/bloodadvances.2022007936 · ExternalCitation · doi-reference
Serum chemistry profiling and prognostication in systemic mastocytosis: A registry-based study of the ECNM and GREM
10.1182/bloodadvances.2024012756 · ExternalCitation · doi-reference
Laboratory Investigation of Deaths Due to Anaphylaxis
10.1520/jfs13095j · ExternalCitation · doi-reference
The serum tryptase test: An emerging robust biomarker in clinical hematology
10.1586/17474086.2014.955008 · ExternalCitation · doi-reference
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
10.18176/jiaci.0675 · ExternalCitation · doi-reference
The Utility of Serum Tryptase as a Marker in Chronic Spontaneous Urticaria
10.2340/00015555-1486 · ExternalCitation · doi-reference
Defining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: Are we there yet?
10.23822/eurannaci.1764-1489.288 · ExternalCitation · doi-reference
Melanoma-derived extracellular vesicles transfer proangiogenic factors
10.32604/or.2024.055449 · ExternalCitation · doi-reference
10.3390/cancers14143474
10.3390/cancers14143474 · ExternalCitation · doi-reference
10.3390/diagnostics13233583
10.3390/diagnostics13233583 · ExternalCitation · doi-reference
10.3390/ijms241512130
10.3390/ijms241512130 · ExternalCitation · doi-reference
10.3390/medicina60091380
10.3390/medicina60091380 · ExternalCitation · doi-reference
Regulation of Human Mast Cell β-Tryptase: Conversion of Inactive Monomer to Active Tetramer at Acid pH
10.4049/jimmunol.160.9.4561 · ExternalCitation · doi-reference
Diagnosis and treatment of Hymenoptera venom allergy
10.5414/alx02430e · ExternalCitation · doi-reference
